Fibrolamellar Carcinoma: A Review with Focus on Genetics and Comparison to Other Malignant Primary Liver Tumors

Fibrolamellar carcinoma is a rare primary malignant liver neoplasm that usually affects adolescents and young adults with no underlying liver disease. Morphologically, the tumor cells resemble oncocytic hepatocytes arranged in cords with a stroma of lamellated collagen fibers. Immunohistochemical studies have found that fibrolamellar carcinomas express markers associated with both biliary (CK7 and epithelial membrane antigen) and hepatocytic (heppar-1and glypican-3) differentiation, as well as markers associated with hepatic progenitor cells (CK19 and EpCAM) and stem cells (CD133 and CD44). Genetic studies show fewer alterations compared with classic hepatocellular carcinoma. Pooled data from comparative genomic hybridization studies show that fibrolamellar carcinomas have fewer and less frequent genomic alterations when compared with classic hepatocellular carcinoma, cholangiocarcinoma, and hepatoblastoma. Of the alterations seen in fibrolamellar carcinoma, the most frequent are gains in 1q and 8q (also frequently seen in other hepatic tumors) and loss of 18q. Fibrolamellar carcinoma also has less frequent methylation of tumor suppressor promoters compared with hepatocellular carcinoma and minimal alterations in mitochondrial DNA. Fibrolamellar carcinoma is associated with better survival than hepatocellular carcinoma and cholangiocarcinoma, presumably due to the young age of the patients and the lack of cirrhosis. These features make more aggressive surgical therapy possible. There is currently very little information on the effectiveness of chemotherapy for fibrolamellar carcinoma.

[1]  Wei Li,et al.  Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. , 2010, International journal of clinical and experimental pathology.

[2]  M. Ladanyi,et al.  Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation , 2010, Modern Pathology.

[3]  Robert E. Brown,et al.  Stemness characteristics of fibrolamellar hepatocellular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma. , 2010, Annals of clinical and laboratory science.

[4]  Y. N. Park,et al.  Hepatic progenitor cells in liver cancers from Asian children , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[5]  M. Torbenson,et al.  Mitochondrial Mutations in Hepatocellular Carcinomas and Fibrolamellar Carcinomas , 2009, Modern Pathology.

[6]  Tonsok Kim,et al.  Liver masses with central or eccentric scar. , 2009, Seminars in ultrasound, CT, and MR.

[7]  Shu Liu,et al.  Fibrolamellar Hepatocellular Carcinoma , 2009, The American Journal of Gastroenterology.

[8]  A. Hackshaw,et al.  Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  B. Sander,et al.  Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. , 2009, Human pathology.

[10]  S. Thorgeirsson,et al.  Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. , 2009, Cancer research.

[11]  M. Torbenson,et al.  Anterior gradient-2 is overexpressed by fibrolamellar carcinomas. , 2009, Human pathology.

[12]  K. Ishak,et al.  Lamellar fibrosis in the fibrolamellar variant of hepatocellular carcinoma: a role for transforming growth factor beta. , 2008, Liver.

[13]  M. Ohira,et al.  The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients , 2008, International journal of cancer.

[14]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[15]  L. Qin,et al.  Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor , 2008, Cancer.

[16]  Zhi-quan Wu,et al.  Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection , 2008, Clinical Cancer Research.

[17]  M. Torbenson,et al.  Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas , 2008, Modern Pathology.

[18]  Jin Woo Kim,et al.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.

[19]  L. Roberts,et al.  Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[20]  M. Harmsen,et al.  Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. , 2007, The American journal of pathology.

[21]  M. Torbenson.  Review of the Clinicopathologic Features of Fibrolamellar Carcinoma , 2007, Advances in anatomic pathology.

[22]  M. Choti,et al.  Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. , 2007, Human pathology.

[23]  A. Adesina,et al.  FOXG1 is overexpressed in hepatoblastoma. , 2007, Human pathology.

[24]  A. Morell,et al.  The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. , 2006, Advances in enzymology and related areas of molecular biology.

[25]  M. Rattray,et al.  A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. , 2006, Gastroenterology.

[26]  E. Lesaffre,et al.  The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin , 2006, Histopathology.

[27]  S. Kakar,et al.  Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. , 2006, Human pathology.

[28]  M. D'Angelica,et al.  Outcome of patients with fibrolamellar hepatocellular carcinoma , 2006, Cancer.

[29]  K. Batts,et al.  Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis , 2005, Modern Pathology.

[30]  M. Torbenson,et al.  Primary liver carcinoma arising in people younger than 30 years. , 2005, American journal of clinical pathology.

[31]  G. Gores,et al.  Erratum: Cholangiocarcinoma (Gastroenterology (2005) 128 (1655-1667)) , 2005 .

[32]  G. Wilczynski,et al.  Carcinoma, a fibrolamellar variant--immunohistochemical analysis of 4 cases. , 2005, Hepato-gastroenterology.

[33]  P. Schirmacher,et al.  Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade – results of an explorative CGH meta-analysis , 2005, British Journal of Cancer.

[34]  Ji-Young Lee,et al.  Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization. , 2005, Cancer genetics and cytogenetics.

[35]  Ji-Young Lee,et al.  Genetic Alterations in Intrahepatic Cholangiocarcinoma as revealed by Degenerate Oligonucleotide Primed PCR-Comparative Genomic Hybridization , 2004, Journal of Korean medical science.

[36]  N. Miyazawa,et al.  A case of postoperative recurrence of fibrolamellar hepatocellular carcinoma with increased vitamin B12 binding capacity in a young Japanese female. , 2004, Japanese journal of clinical oncology.

[37]  H. El‐Serag,et al.  The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.

[38]  H. El‐Serag,et al.  Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population‐based study , 2004, Hepatology.

[39]  J. Quinn,et al.  Fibrolamellar hepatocellular carcinoma in children and adolescents , 2003, Cancer.

[40]  L. Terracciano,et al.  Cytogenetic alterations in liver cell tumors as detected by comparative genomic hybridization. , 2003, Pathologica.

[41]  N. Wong,et al.  Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. , 2002, Journal of hepatology.

[42]  W. Kim,et al.  Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. , 2002, Human pathology.

[43]  M. Choti,et al.  Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling. , 2002, Human pathology.

[44]  G. Perilongo,et al.  Surgical view of the treatment of patients with hepatoblastoma , 2002, Cancer.

[45]  C. Ihm,et al.  Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. , 2001, Cancer genetics and cytogenetics.

[46]  J. Klempnauer,et al.  Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization. , 2000, American Journal of Clinical Pathology.

[47]  C. Larsson,et al.  Comparative genomic hybridization reveals population-based genetic alterations in hepatoblastomas , 2000, British Journal of Cancer.

[48]  P. Pineau,et al.  Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients , 2000, Oncogene.

[49]  P. Lichter,et al.  Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. , 2000, The American journal of pathology.

[50]  Jie Hu,et al.  Comparative genomic hybridization analysis of hepatoblastomas , 2000, Genes, chromosomes & cancer.

[51]  T. Ichikawa,et al.  Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. , 1999, Radiology.

[52]  G. Tomlinson,et al.  Comparative genomic hybridization analysis of hepatoblastomas: additional evidence for a genetic link with Wilms tumor and rhabdomyosarcoma , 1999, Cytogenetic and Genome Research.

[53]  W. Jarnagin,et al.  An analysis of 412 cases of hepatocellular carcinoma at a Western center. , 1999, Annals of surgery.

[54]  S. Hirohashi,et al.  Cloning of the gene gob-4, which is expressed in intestinal goblet cells in mice. , 1999, Biochimica et biophysica acta.

[55]  R. Abrams,et al.  Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. , 1999, American journal of clinical oncology.

[56]  A. Clarke,et al.  Smad4 (DPC4)--a potent tumour suppressor? , 1998, British Journal of Cancer.

[57]  M. Wolter,et al.  Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[58]  D. Betts,et al.  A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype. , 1997, Medical and pediatric oncology.

[59]  V. Tonk,et al.  Report of a complex karyotype in recurrent metastatic fibrolamellar hepatocellular carcinoma and a review of hepatocellular carcinoma cytogenetics. , 1996, Cancer genetics and cytogenetics.

[60]  K. Ishak,et al.  DNA ploidy of fibrolamellar hepatocellular carcinoma by image analysis. , 1994, Human pathology.

[61]  J. Dooley,et al.  Infrequent chromosome allele loss in fibrolamellar carcinoma. , 1993, British Journal of Cancer.

[62]  J. Dooley,et al.  Loss of constitutional heterozygosity on chromosome 5q in hepatocellular carcinoma without cirrhosis. , 1991, British Journal of Cancer.

[63]  V. Desmet,et al.  Abundant expression of cytokeratin 7 in fibrolamellar carcinoma of the liver , 1990, Histopathology.

[64]  P. Scheuer,et al.  An immunohistochemical and ultrastructural study of the sinusoids of hepatocellular carcinoma , 1990, Cancer.

[65]  D. Sheahan,et al.  Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. , 1988, Human pathology.

[66]  S. Lelcuk,et al.  [Fibrolamellar carcinoma of the liver]. , 1987, Harefuah.

[67]  M. Kew,et al.  Serum vitamin B12 binders in south african blacks with hepatocellular carcinoma , 1985, Cancer.

[68]  S. Bloom,et al.  NEUROTENSIN SECRETION BY FIBROLAMELLAR CARCINOMA OF THE LIVER , 1984, The Lancet.

[69]  D. Bradbury,et al.  High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. , 1983, British medical journal.

[70]  S. Silverberg,et al.  Ultrastructure of fibrolamellar oncocytic hepatoma , 1982, Cancer.

[71]  N. P. Libbey,et al.  Hepatocellular carcinoma. Polygonal cell type with fibrous stroma—an atypical variant with a favorable prognosis , 1980, Cancer.

[72]  M. Omata,et al.  Fibrolamellar carcinoma of the liver: A tumor of adolescents and young adults with distinctive clinico‐pathologic features , 1980, Cancer.

[73]  S. Waxman,et al.  The clinical and physiological implications of hepatoma B12-binding proteins. , 1977, Cancer research.

[74]  R. L. Burger,et al.  Isolation and characterization of a novel vitamin B12-binding protein associated with hepatocellular carcinoma. , 1975, The Journal of clinical investigation.

[75]  S. Waxman,et al.  Characteristics of a Novel Serum Vitamin‐B12‐Binding Protein Associated with Hepatocellular Carcinoma , 1974, British journal of haematology.

[76]  S. Waxman,et al.  A tumor-related vitamin B12 binding protein in adolescent hepatoma. , 1973, The New England journal of medicine.

[77]  H. Edmondson.  Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. , 1956, A.M.A. journal of diseases of children.

[78]  P. Bejarano.  Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum , 2010 .

[79]  S. Kakar,et al.  Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization , 2009, Modern Pathology.

[80]  R. Peters,et al.  Mitochondrial abnormalities in hepatocytes adjacent to fibrolamellar hepatocellular carcinoma , 2008, Journal of Tongji Medical University.

[81]  C. Bellamy,et al.  Fibrolamellar hepatocellular carcinoma. , 2005 .

[82]  P. Takvorian.  [Tumors of the liver in children]. , 1988, Pediatrie.

[83]  W. Luck,et al.  Transcobalamin I as a "marker" for fibrolamellar hepatoma. , 1986, Medical and pediatric oncology.